According to a new report, by GlobalData forecasts that the burden of diagnosed HER2+/HR+ breast cancer is expected to increase at an annual growth rate (AGR) of 1.70% from around 100,000 cases in 2020 to 114,000 cases in 2030 in the eight major markets, including the United States, France, Germany, Italy, Spain, the UK, Japan, and urban China.

In their latest report, HER2-Positive Breast Cancer: Epidemiology Forecast to 2030, GlobalData reveals that the increase is partly attributed to the moderately rising trend in incidence in the 8 major markets, combined with underlying demographic changes in the respective markets.

PR13956 2.pngHER2-positive breast cancer consists of HER2+/HR+ and HER2+/HR- subtypes. In the 8MM, HER2+/HR+ was the most common subtype of HER2-positive breast cancer, followed by HER2+/HR- breast cancer.

“Although HER2+/HR+ was the most common type, our research shows that cases of HER2+/HR- breast cancer are also growing steadily in the 8 major markets. This is important as HER2-positive cancer overall is more aggressive than HER2-negative cancer,” noted Bishal Bhandari, Ph.D., Senior Epidemiologist at GlobalData.

In the 8 major markets, the majority of diagnosed incident cases of HER2-positive cases were in stage I–III, and fewer than 10% of cases were in stage IV in 2020.

Advertisement #3

“It is a promising development that the majority of breast cancer cases are now diagnosed at earlier stages, which improves breast cancer survival and response to treatment. However, due to a longer life expectancy in breast cancer patients, the overall number of individuals with breast cancer will continue to increase over time,” Bhandari added.

In the report, the researchers discuss:

  • HER2-Positive Breast Cancer Epidemiology Report and Model provide an overview of the risk factors and global trends of HER2-positive in the eight major markets.
  • This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 8 major markets: diagnosed incident cases of all invasive, HER2+/HR+, and HER2+/HR- breast cancer; diagnosed five-year prevalent cases of HER2+/HR+, and HER2+/HR- breast cancer; and diagnosed incident cases of HER2+/HR+ and HER2+/HR- breast cancer by cancer staging. Additionally, diagnosed incident cases of HER2+HR+ and HER2+/HR- breast cancer cases are further segmented by metastasis and biomarker expression. HER2+/HR+ and HER2+/HR- breast cancer cases are also segmented by menopausal status.
  • The HER2-Positive Epidemiology Report and Model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

The report’s Key Highlights

  • Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide, accounting for 25.2% of all incident cases of female cancers, making the disease exceedingly prevalent. Breast cancer is classified based on human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status (American Cancer Society, 2019). HER2-/HR+ and HER2-/HR- were analyzed in the HER2-negative breast cancer report. This report explores HER2-positive breast cancer, namely, HER2+/HR+ and HER2+/HR- breast cancer.
  • GlobalData epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, taking into account the significant relationship between age and HER2-positive breast cancer. GlobalData epidemiologists applied country-specific incidence rates of HER2-positive breast cancer wherever available, to each country’s population to obtain the number of estimated diagnosed incident cases.
  • The following data describes the epidemiology of HER2+/HR+ and HER2+/HR- cases. In 2020, the 8MM had 97,308 diagnosed incident cases of HER2/HR+ breast cancer. This is expected to increase to 113,608 diagnosed incident cases by 2030, at an Annual Growth Rate (AGR) of 1.68%. In the 8 major markets, the diagnosed incident cases of HER2+/HR- breast cancer will increase from 53,824 cases in 2020 to 63,106 cases in 2030, at an AGR of 1.72%. This increase is partly attributed to the moderately rising trend in historical incidence in the 8MM, combined with underlying demographic changes in the respective markets. The early diagnosis and development of more effective therapies would improve survival from HER2-positive breast cancer.

Featured image: Doctor discussing treatment options with a patient. Photo courtesy: 2016 – 2021 © Fotolia/Adobe. Used with permission.

Advertisement #5